Top

Published in:

01-06-2020 | Neurological Tests | COVID-19

Assessing disability and relapses in multiple sclerosis on tele-neurology

Authors: Marcello Moccia, Roberta Lanzillo, Vincenzo Brescia Morra, Simona Bonavita, Gioacchino Tedeschi, Letizia Leocani, Luigi Lavorgna, on behalf of the Digital Technologies Web and Social Media Study Group of the Italian Society of Neurology

Published in: Neurological Sciences | Issue 6/2020

Abstract

Background

As a consequence of the coronavirus disease 2019 (COVID-19) pandemic, a large amount of consultations will be delivered through tele-medicine, especially for diseases causing chronic disability and requiring immunomodulatory treatments, such as multiple sclerosis (MS).

Methods

We have hereby reviewed available tools for tele-neurology examination in MS, including components of neurological examination that can be assessed through video, patient-reported outcome measures (PROMs), and digital technology.

Results

Overall, we have suggested a battery for assessing MS disability and relapses on tele-medicine, which brings together conventional examination, PROMs (e.g., Patient Determined Disease Steps, MS Impact Scale), and cognitive tests (Symbol Digit Modalities Test) that can be delivered remotely and in multiple languages.

Discussion

The use of common tools for neurological examination could improve tele-neurology practice for both general neurologists and MS specialists, and quality of care for people with MS.

Bonavita S, Tedeschi G, Atreja A, Lavorgna L (2020) Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic. Neurol Sci

Waldman G, Mayeux R, Claassen J et al (2020) Preparing a neurology department for SARS-CoV-2 (COVID-19): early experiences at Columbia University Irving Medical Center and the New York Presbyterian Hospital in New York City. Neurology.

Brownlee W, Bourdette D, Broadley S et al (2020) Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology.

Tur C, Moccia M, Barkhof F et al (2018) Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol 14:75–93CrossRef

American Academy of Neurology (2020) Telemedicine and remote care. In: AAN COVID-19 Neurol. Resour. Cent. https://www.aan.com/tools-and-resources/practicing-neurologists-administrators/telemedicine-and-remote-care/. Accessed 19 Apr 2020

Galán-Mercant A, Cuesta-Vargas AI (2014) Mobile Romberg test assessment (mRomberg). BMC Res Notes 7:640CrossRef

Lavorgna L, Brigo F, Moccia M et al (2018) e-Health and Multiple Sclerosis: an update. Mult Scler 24:1657–1664CrossRef

Robb JF, Hyland MH, Goodman AD (2019) Comparison of telemedicine versus in-person visits for persons with multiple sclerosis: a randomized crossover study of feasibility, cost, and satisfaction. Mult Scler Relat Disord 36:101258CrossRef

Yeroushalmi S, Maloni H, Costello K, Wallin M (2019) Telemedicine and multiple sclerosis: a comprehensive literature review Samuel. J Telemed Telecare

10.

Bove R, Bevan C, Crabtree E et al (2019) Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. Mult Scler 25:1526–1534CrossRef

11.

Lavorgna L, Sparaco M, Esposito S et al (2017) Validity and reproducibility of the Italian version of the patient determined disease steps scale in people with multiple sclerosis. Mult Scler Relat Disord 18:173–176CrossRef

12.

Learmonth YC, Motl RW, Sandroff BM et al (2013) Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 13:37CrossRef

13.

Wojcik C, Beier M, Costello K et al (2019) Computerized neuropsychological assessment devices in multiple sclerosis: a systematic review. Mult Scler 25:1848–1869CrossRef

14.

Silva PHR, Spedo CT, Barreira AA, Leoni RF (2018) Symbol Digit Modalities Test adaptation for Magnetic Resonance Imaging environment: a systematic review and meta-analysis. Mult Scler Relat Disord 20:136–143CrossRef

15.

Chataway J, Porter B, Riazi A et al (2006) Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. Lancet Neurol 5:565–571CrossRef

16.

Hobart J, Lamping D, Fitzpatrick R et al (2001) The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 124:962–973CrossRef

17.

Bigi S, Marrie RA, Till C et al (2017) The computer-based Symbol Digit Modalities Test: establishing age-expected performance in healthy controls and evaluation of pediatric MS patients. Neurol Sci 38:635–642CrossRef

Title: Assessing disability and relapses in multiple sclerosis on tele-neurology
Authors: Marcello Moccia
Roberta Lanzillo
Vincenzo Brescia Morra
Simona Bonavita
Gioacchino Tedeschi
Letizia Leocani
Luigi Lavorgna
on behalf of the Digital Technologies Web and Social Media Study Group of the Italian Society of Neurology
Publication date: 01-06-2020
Publisher: Springer International Publishing
Keywords: Neurological Tests
Multiple Sclerosis
COVID-19
Published in: Neurological Sciences / Issue 6/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04470-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Assessing disability and relapses in multiple sclerosis on tele-neurology

Abstract

Background

Methods

Results

Discussion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Discussion

Please log in to get access to this content

Other articles of this Issue 6/2020

Serial change of opsoclonus associated with Mycoplasma pneumoniae infection

Management of dysphagia in Huntington’s disease: a descriptive review

Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2

A case of Bickerstaff encephalitis associated with Mycoplasma pneumoniae infection

Diagnosing herpes simplex-1 encephalitis at the time of COVID-19 pandemic

An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID)